The Latest Cardiac and Vascular News
VANCOUVER, British Columbia, Nov. 29, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces the release of the Company’s Condensed Consolidated Interim Financial Statements and the Management’s Discussion and Analysis for the three and nine […]
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018. Over the summer, the Company […]
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry […]
VANCOUVER, British Columbia, July 02, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the results of its recent Annual General Meeting. The Company is pleased to announce […]
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo […]
